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REP1 inhibits FOXO3-mediated apoptosis to promote
cancer cell survival
Kwon-Ho Song1,2,3,14, Seon Rang Woo1,2,4,14, Joon-Yong Chung5, Hyo-Jung Lee1,2,3, Se Jin Oh1,2,3, Soon-Oh Hong1,2,3, Jaegal Shim6,
Yong Nyun Kim6, Seung Bae Rho7, Seung-Mo Hong8, Hanbyoul Cho5,9, Masahiko Hibi10, Dong-Jun Bae11, Sang-Yeob Kim11,12,
Min Gyu Kim13, Tae Woo Kim*,1,2,3,4 and Young-Ki Bae*,6
Rab escort protein 1 (REP1) is a component of Rab geranyl-geranyl transferase 2 complex. Mutations in REP1 cause a disease
called choroideremia (CHM), which is an X-linked eye disease. Although it is postulated that REP1 has functions in cell survival or
death of various tissues in addition to the eye, how REP1 functions in normal and cancer cells remains to be elucidated. Here, we
demonstrated that REP1 is required for the survival of intestinal cells in addition to eyes or a variety of cells in zebrafish, and also
has important roles in tumorigenesis. Notably, REP1 is highly expressed in colon cancer tissues and cell lines, and silencing of
REP1 sensitizes colon cancer cells to serum starvation- and 5-FU-induced apoptosis. In an effort to elucidate the molecular
mechanisms underlying REP1-mediated cell survival under those stress conditions, we identified FOXO3 as a binding partner
of REP1 using a yeast two-hybrid (Y2H) assay system, and we demonstrated that REP1 blocked the nuclear trans-localization of
FOXO3 through physically interacting with FOXO3, thereby suppressing FOXO3-mediated apoptosis. Importantly, the inhibition
of REP1 combined with 5-FU treatment could lead to significant retarded tumor growth in a xenograft tumor model of
human cancer cells. Thus, our results suggest that REP1 could be a new therapeutic target in combination treatment for colon
cancer patients.
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Forkhead box transcription factor class O (FOXO) proteins are
important regulators that participate in a variety of cellular
processes including cell cycle progression, programmed cell
death, stress detoxification, DNA damage repair, glucose
metabolism, and differentiation.1,2 In mammals, this Forkhead
subfamily consists of four members, of which the three
predominant members, FOXO1 (also known as FKHR),
FOXO3 (also known as FKHRL1) and FOXO4 (also known
as AFX), display a high degree of redundancy in function.3,4 In
cancer, FOXOs are considered as tumor suppressor genes
because combined somatic deletion of the subfamily causes a
progressive cancer-prone condition.5–7 FOXOs participate in
the processes of apoptosis and cell cycle arrest by regulating
the transcription of genes involved in apoptosis, cell cycle
regulation and DNA damage repair.8 Specifically, the tran-
scriptional functions and subcellular localization of FOXOs are
regulated in part by PI3K/Akt signaling which phosphorylates
FOXOs to promote interaction with 14-3-3 protein, resulting in
nuclear export and ubiquitin proteasome pathway-dependent
degradation of FoxOs.9,10 Of these, FOXO3 is highly
expressed in normal tissue, while it is either reduced or
restricted to the cytoplasm in tumor tissues.6,11,12 Collectively,
inactivation of FOXOs appears to be a crucial stage in
tumorigenesis; hence, restoring the activity of these factors
could be a potential effective therapeutic strategy. In addition,
modulation of subcellular translocation of FOXOs could
provide another possible strategy.
Rab escort protein 1 (REP1) is a cofactor of Rab geranyl-
geranyl transferase 2 (GGTase 2), which functions in geranyl-
geranyl modification of C-terminal cysteine residues of new-
born Rab GTPases that are essential for regulating vesicle
trafficking.13,14 Mutations in REP1 in humans cause a disease
called choroideremia (CHM) which is an X-linked eye disease
characterized by progressive degeneration of retinal pigment
epithelium, photoreceptors, and choroid.15,16 Meanwhile, in
mammals, there is an additional REP1-like protein, REP2,
which may partially compensate the function of REP1 in most
of tissues except eyes, thereby CHM phenotype is mainly
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restricted in eyes.17,18 The functional study of REP1 using
animal models also showed that the mutation of the REP1
gene causes defects in photoreceptors and retinal pigment
epithelium accompanied by reduction in the number of
melanosomes in mice,19,20 and leads to destruction of hair
cells and photoreceptor degeneration in zebrafish.21,22 Apart
from the characteristic eye degeneration phenotype, the
knockout of REP1 led to abnormal trophoblast development
and vascularization in extra-embryonic tissues in mice,23 and
uninflated swim bladders and edema of the heart and
abdomen were observed in rep1 mutant zebrafish.18 Thus, it
is supposed that REP1 has functions in cell survival or death of
various tissues in addition to eyes; however, how the functions
of REP1 are controlled in normal and cancer cells remains to
be elucidated.
In the present study, we verified that REP1 has important
roles in normal development of intestinal cells in zebrafish in
addition to eyes, and demonstrated that REP1 function in
tumorigenesis, especially colon cancer cell survival under
serum starvation- or 5-FU-mediated stress conditions.
Furthermore, we show herein novel insights into the roles of
REP1 in FOXO3-mediated apoptosis under stress conditions.
Results
Cell survival was impaired in the intestine of rep1−/−
mutant zebrafish embryos. The mutant for zebrafish rab
escort protein 1 (rep1) gene was originally screened as the
evanescence (evark10) mutant that displayed loss of granular
cells and reduction of Purkinje cells in the cerebellum.24
Positional cloning identified that the evanescence mutant
phenotype was caused by the mutation of the rep1 gene, and
the truncated form of mutant REP1 protein does not have
normal function (unpublished data). The major morphological
changes of evark10 mutant were small, under-pigmented
eyes, similar to those in the previously reported alleles of
rep1 mutants (Figure 1c).21,22 In addition to eye defects, we
found that the length of intestine was shortened and it was
malformed in mutants compared with wild-type embryos at
5 days post fertilization (dpf) (Figure 1b and d). To examine
whether the malformed the intestine in mutants could be due
to cell survival defects, we counted the number of TUNEL-
positive apoptotic cells in intestines of normal and mutant
zebrafish. The number of apoptotic cells was dramatically
increased in intestine of rep1 mutants; meanwhile, apoptotic
cells were merely detected in the intestine and other tissues
in the zebrafish trunk of wild-type embryos (Figure 1e and f).
The increase of apoptotic cell death in intestine of rep1
mutant embryos was further confirmed by immunostaining
with anti-caspase-3 antibody. Consistently, there were very
few red fluorescent-positive apoptotic cells in the intestine of
wild-type embryos (Figure 1g). In contrast, numerous
activated caspase-3-positive apoptotic cells were detected
in the intestine as well as the stomach of rep1 mutant
embryos without any defects in blood vessel structures
marked by green fluorescence (Figure 1h). These data imply
that the normal function of rep1 gene is necessary for
intestine cell survival in the zebrafish embryos.
Silencing of REP1 sensitizes colon cancer cells to serum
starvation- and 5-FU-induced apoptosis. As knockout of
rep1-impaired cell survival in the intestine of zebrafish, we
hypothesized that functions of REP1 protein associated with
cell survival are not only confined to embryonic cells but they
also apply to human cells derived from the intestine. To
address it, firstly, we determined REP1 expression levels in
normal colon tissues and colon cancer tissues. REP1
proteins were highly expressed in colon cancer tissues
compared with the normal colon (Po0.0001, Figure 2a). In
addition, we determined REP1 expression in normal colon
cells (FHC) and colon cancer cells (LoVo, SNUC4, HT29, and
HCT116). REP1 was highly expressed in colon cancer cells
compared with normal colon cells (Figure 2b). These data
suggest that REP1 is prominently expressed in colon cancer
cells and it could be involved in cancer progression. There-
fore, we further verified REP1 functions in survival of HCT116
and LoVo colon cancer cells. There was no considerable
difference in cell survival between REP1-silenced colon
cancer cells (siREP1) and controls (siGFP) under normal
serum condition (data not shown). However, proliferation of
siREP1-treated cells was significantly decreased compared
with that in controls in a time-dependent manner under
serum-starved condition (Figure 2c). In addition, the apoptotic
cells were increased about three-fold in each colon cancer
cell line by knockdown of REP1 after 72 h under starvation
(Figure 2d) and, consistently, the levels of pro-apoptotic
molecules such as BIM and BAK, and CDK inhibitor p27,
were also increased (Figure 2e). Furthermore, the siREP1-
treated HCT116 and LoVo cells (siREP1, IC50= 53.22 and
83.79 uM, respectively) were more susceptible to the anti-
tumor effect of 5-fluorouracil (5-FU) than the siGFP-treated
HCT116 and LoVo cells (siGFP, IC50=12.85 and 15.75 uM,
respectively) (Figure 2f). Notably, the siREP1-transfected
colon cancer cells were much more vulnerable to apoptosis
induced by 5-FU than siGFP-transfected cells (Figure 2g).
Taken together, these data indicate that REP1 is required for
survival of colon cancer cells against apoptotic cell death
induced by the anti-cancer drug 5-FU as well as in serum
starvation.
REP1 confers resistance to serum starvation- and 5-FU-
induced apoptosis. In addition to loss-of-function studies,
we carried out gain-of-function studies for REP1. According
to our unpublished data, C-terminal region truncation of the
REP1 protein causes the evanescence mutant phenotype in
zebrafish, suggesting that the mutant form of REP1 does not
have the normal function of REP1. To address this, we
constructed a mimetic truncated mutant (REP1 Mut) of the
zebrafish REP1 mutant, and then, we introduced wild-type
REP1 (REP1 WT) and REP1 Mut into HEK293 cells which
have low expression of REP1 (Supplementary Figure 1).
REP1 WT-transfected cells showed decreased expression of
BAK, BIM, and p27 compared with empty vector (no)-
transfected cells (Figure 3a). However, transfection of REP1
Mut failed to cause markedly decrease in the expression of
BAK, BIM, and p27 (Figure 3a). Transfection of REP1 WT
accelerated the growth of HEK293 cells, whereas transfec-
tion of REP1 Mut had no substantial impact on cell growth
(Figure 3b). Notably, transfection of REP1 WT into HEK293
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Figure 1 Cell survival was impaired in the intestine of rep1−/− mutant zebrafish embryos. (a and c) Dorsal view images of wild-type zebrafish (a) and rep1−/− mutant
zebrafish embryos (c). Lateral view images of wild-type (b) and rep1−/−mutant zebrafish embryos (d) at 5 days post fertilization (dpf). (d) Defective eye morphology was detected
in rep1−/− mutant embryos. The length of the intestine of rep1−/− mutant embryo was shortened and it was malformed (white arrow in d). (e and f) TUNEL assays with wild-type
(e) and Rep1−/− mutant embryos (f). Extensive TUNEL labeling was observed in the intestine of rep1−/− mutant embryos. (g and h) Immunostaining with anti-caspase-3 in wild-
type Tg(flk:gfp) (g) and rep1−/− mutant Tg(flk:gfp) embryos (h). Apoptotic cell death was detected in the intestine of rep1−/− mutant Tg(flk::egfp) embryos (red fluorescence
indicated with white arrow in h) as well as in the stomach of these embryos (yellow arrow in h). Blood vessels were visualized with green fluorescence (g and h). All images were
lateral views except for (a) and (c) at 5 dpf. Scale bar, 200 μm
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cells reduced apoptosis induced by serum starvation and
5-FU, while transfection of REP1 Mut did not significantly alter
the susceptibility of HEK293 cells to apoptotic stimuli (Figure
3c and d). Collectively, these data indicate that REP1 is able
to confer resistance to apoptosis which is induced by serum
starvation or anti-tumor drug 5-FU, and the C-terminal region
of the REP1 protein is important for the anti-apoptotic
function of REP1.
REP1 physically interacts with FOXO3. Although it has
been suggested that REP1 has a crucial role in survival and
resistance of colon cancer cells against an anti-cancer drug
through conferring anti-apoptotic properties to cells, the
underlying mechanism how REP1 confers anti-apoptotic
function to cells is largely unknown. To gain insight into the
role of REP1 in cell survival and chemo-resistance, we
employed a yeast two-hybrid system (Y2H) in vivo and
screened FOXO3 as a potential REP1-interacting protein. To
confirm this result, positive interaction was evaluated using
both cell growth on leucine-deficient plates and o-nitrophenyl
β-D-galactopyranoside (ONPG) β-galactosidase activity. As
shown in Figure 4a and b, β-galactosidase activity was fully
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activated (92.22±1.29) for the interaction between REP1
and FOXO3 but it was not activated with the empty-insert
plasmid (no insert: 1.38±0.55). To confirm our Y2H results,
we carried out co-immunoprecipitation (co-IP) by immuno-
precipitation with either anti-HA (FOXO3) or anti-FLAG
(REP1) antibody from lysates of HEK293 cells transfected
with FOXO3 tagged HA (FOXO3-HA) and REP1-tagged
FLAG (REP1-FLAG). Under the IP condition by the anti-HA
antibody, only REP1 WT co-precipitated with HA-FOXO3,
whereas REP1 Mut did not co-precipitate with HA-FOXO3
(Figure 4c, left). Likewise, under IP using anti-FLAG, only
REP1 WT co-precipitated with FOXO3 (Figure 4c, middle).
Moreover, endogenous REP1 could indeed co-precipitate
with FOXO3, and reciprocal IP using anti-REP1 antibody also
pulled down FOXO3 (Figure 4d and e). These findings
suggest that REP1 physically interacts with FOXO3 and the
C-terminal region of the REP1 protein is required for the
interaction.
siREP1-induced cell death was alleviated by inhibition of
FOXO3 in colon cancer cells. As FOXO3 is a crucial
regulator of apoptosis induced by various stress stimuli or
anti-cancer drugs, we next examined whether FOXO3 is
required for siREP1-mediated apoptosis under serum-
starved conditions and 5-FU treatment. To test this possibility,
HCT116 cells were transfected with siGFP or siREP1,
together with or without siFOXO3. As observed in
Figure 2e, when REP1 was knocked down alone, the
expression level of BIM, BAK, and p27 was increased,
respectively. Interestingly, even when REP1 was knocked
down, the expressions of BIM, BAK, and p27 were not
affected if FOXO3 was knocked down (Figure 5a). To further
reproduce these phenomena, we repeated the above
experiments under serum-starved condition. Consistently,
siREP1-transfected cells were less resistant to serum-
starved condition and apoptosis than siGFP-transfected cells
(Figure 5b and c). However, when we knocked down REP1
and FOXO3 together, we observed a higher number of viable
cells and a lower number of apoptotic cells than in REP1
knockdown alone cells (Figure 5b and c). In addition, we also
performed cell viability assay under an apoptotic condition
induced by 5-FU. Similarly, the negative effect of REP1
knockdown on cell survival was reduced when FOXO3 was
knocked down simultaneously (Figure 5d and e). All of these
Figure 2 Silencing of REP1 sensitizes colon cancer cells to serum starvation- and 5-FU-induced apoptosis. (a) Immunohistochemical staining of REP1 was performed on
tissue microarray of human colon cancer specimens. Representative images of immunohistochemical staining of REP1 in colon tissues from normal and carcinoma patients.
High-magnification images are shown in inset. Scale bar, 100 μm. (b) Protein expression of REP1 in normal colon cells (FHC) and colon cancer cells (LoVo, SNUC4, HT29,
HCT116) was determined by immunoblotting. β-ACTIN was included as an internal loading control. Numbers below blots indicate the expression as measured by fold change.
(c–e) HCT116 and LoVo cells were transfected with siRNAs targeting GFP or REP1. (c) Growth rate of siGFP- versus siREP1-transfected HCT116 and LoVo cells in serum
starvation culture (0.1% FBS). Cells were harvested at the indicated times and counted after trypan blue staining to exclude dead cells. (d) Flow cytometry analysis of the
frequency of apoptotic (active caspase-3+) cells among siGFP- or siREP1-transfected HCT116 and LoVo cells. Isotype control staining is indicated by solid gray regions and anti-
active caspase-3 staining is indicated by black dotted-lines. (e) Expressions of REP1, BIM, BAK, BID, BAX, BAD, and p27 were analyzed by immunoblotting. β-ACTIN was
included as an internal loading control. Numbers below blots indicate the expression as measured by fold change. (f and g) HCT116 and LoVo cells were transfected with siRNAs
targeting GFPor REP1. Cells were treated with the indicated concentrations of 5-FU for 24 h. (f) Viability of siGFP- or siREP1-transfected HCT116 and LoVo was measured by an
MTTassay, and then the concentrations resulting in 50% inhibition of cell viability (IC50 values) were determined. Each experiment was performed in triplicate, and error bars
represent S.D. from the mean. (g) Flow cytometry analysis of the frequency of apoptotic (active caspase-3+) cells among siGFP- or siREP1-transfected HCT116 and LoVo cells.
Isotype control staining is indicated by solid gray regions and anti-active caspase-3 staining is indicated by black dotted-lines. All Graphs represent two independent experiments
performed in triplicate. Error bars represent S.D. from the mean. *Po0.01, **Po0.001
Figure 3 REP1 confers resistance to serum starvation- and 5-FU-induced apoptosis. HEK293 cells were transfected with empty vector (no), REP1 wild-type (WT) or REP1
mutant (Mut). (a) Expressions of FLAG (REP1), BIM, BAK, and p27 were analyzed by immunoblotting. β-ACTIN was included as an internal loading control. Numbers below blots
indicate the expression as measured by fold change. (b) Growth rate of transfected cells in serum-starvation culture (0.1% FBS). Cells were harvested at the indicated times and
counted after trypan blue staining to exclude dead cells. (c) The frequency of apoptotic (active caspase-3+) cells among the transfected cells cultured in serum-starvation
condition (0.1% FBS) was estimated by flow cytometry analysis. (d) Transfected cells were treated with 50 uM of 5-FU for 24 h and then the frequency of apoptotic (active
caspase-3+) cells was determined by flow cytometry analysis. All graphs represent two independent experiments performed in triplicate. Error bars represent S.D. from the mean.
*Po0.01, **Po0.001
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data led us to the conclusion that siREP1-mediated cell death
was alleviated by inhibition of FOXO3, that is, REP1 could
function in cell survival under various stress conditions by
conferring negative effects to FOXO3-dependent apoptosis in
colon cancer cells.
REP1 negatively regulates the transcriptional activity of
FOXO3 and the expression of FOXO3 target genes.
Transcription factor FOXO3 controls cell death via upregulat-
ing transcription of genes related to apoptosis or cell cycle
arrest such as BIM, BAK, and p27.25 To confirm that REP1
inhibits FOXO3 function, we used the FHRE-Luc reporter
system, which expresses luciferase when FOXO binds to
FHRE. To assess the transcriptional activity of FOXO3 in the
presence of REP1, HCT116 cells were transfected with
siGFP or siREP1. Relative reporter activity in siREP1 group
was significantly increased, compared with that in siGFP
(Figure 6a). Notably, the expression of FOXO3 target genes
such as BAK, BIM, and p27 was increased when REP1 was
knocked down (Figure 6b). To confirm the inhibitory effect of
REP1 on FOXO3 transcriptional activity, we overexpressed
the wild-type and mutant REP1 in HEK293 cells, and then
analyzed the transcriptional activity of FOXO3 with FHRE-
Luc. Consistently, when HEK293 cells were transfected with
wild-type REP1, FOXO3-mediated reporter activity was
significantly reduced (Figure 6c). However, mutated REP1
did not inhibit FOXO3-mediated reporter activity (Figure 6c).
Also, the transcription level of all three FOXO3 target genes
was decreased when wild-type REP1 was overexpressed,
whereas mutant REP1-overexpressing cells did not show a
remarkable difference from no insert (Figure 6d). From these
data, we concluded that REP1 negatively regulates the
transcriptional activity of FOXO3 and the expression of
FOXO3 target genes, including BAK, BIM, and p27.
REP1 inhibits nuclear trans-localization of FOXO3. Being
a transcription factor, FOXO3 activity is highly influenced by
its subcellular localization. Since REP1 silencing did not alter
the expression of FOXO3 (see Figure 5a), we reasoned that
the inhibitory function of REP1 on transcriptional activity of
FOXO3 might be associated with trans-localization of
FOXO3. To test this possibility, we examined the subcellular
localization of FOXO3 depending upon REP1 expression by
transfecting RFP-FOXO3 plasmid into HEK293 cells. When
we transfected the empty vector (no insert), RFP-FOXO3
proteins were mainly localized within the nucleus rather than
the cytoplasm. However, RFP-FOXO3 proteins were defi-
nitely localized in the cytoplasm of HEK293 cells which were
transfected with REP1 WT, while REP1 Mut did not affect the
localization of FOXO3 (Figure 7). Furthermore, the majority of
RFP-FOXO3 proteins in siGFP-transfected HCT116 cells
were localized in the cytoplasm. However, in the absence of
Figure 4 REP1 interacts with FOXO3. (a and b) Positive protein–protein interactions were determined by monitoring cell growth over 3 days on a medium lacking leucine (a),
and by the formation of blue colonies on X-gal plates containing galactose at 30 °C (b). The values of β-galactosidase activity (unit) estimated by adding o-nitrophenyl β-D-
galactopyranoside (ONPG) are indicated below their corresponding lanes. Graph represents two independent experiments performed in triplicate. Error bars represent S.D. from
the mean. **Po0.001. (c) Co-immunoprecipitation of REP1 and FOXO3. HEK293 cells were co-transfected with the indicated constructs. Lysates of the transfected cells
immunoprecipitated with anti-HA antibody (left) or anti-FLAG antibody (middle), followed by western blotting using anti-FOXO3 and anti-REP1 antibodies. The input represents
5% of whole-cell lysates (WCL) used in immunoprecipitation (right). (d–e) Endogenous REP1 binds to endogenous FOXO3 in HCT116 cells. Immunoprecipitation was performed
using rabbit IgG, anti-FOXO3 (d) or anti-REP1 (e), followed by western blotting using the indicated antibodies
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REP1, RFP-FOXO3 proteins re-localized themselves within
the nucleus (Supplementary Figure 2). From all these
data, we could finally conclude that REP1 directly binds to
FOXO3 proteins and holds back their re-localization from the
cytoplasm to the nucleus.
Inhibition of REP1 enhances the anti-tumor effect of
5-FU. Because REP1 expression confers resistance to 5-FU
in vitro, we reasoned that inhibition of REP1 may serve as an
interventional strategy for 5-FU-based cancer therapy. To test
the therapeutic value of REP1 inhibition, we inoculated
HCT116 cells into nude mice, and 10 days later, we knocked
down the REP1 expression by intravenous administration of
chitosan nanoparticles (CNP) carrying REP1- or GFP-
targeting siRNA, according to the schedule described in
Figure 8a. CNPs have been previously demonstrated to be
highly efficient in delivering siRNA into the tumor mass via the
enhanced permeability and retention effect.26,27 Fourteen
days after tumor challenge, chitosan hydrogels (CHs) loaded
with 5-FU (0.1 mg/kg) were administered intratumorally
(Figure 8a). Delivery of siREP1 alone elicited a profound
therapeutic effect, and, more importantly, when combined
with 5-FU treatment, the tumor burden was significantly
reduced compared with siREP1 alone or 5-FU treatment
combined with control siRNA at 23 days after tumor
challenge (Figure 8b and c). Taken together, our data
demonstrate that inhibition of REP1 represents a promising
strategy for anti-cancer therapy.
Discussion
According to previous reports, a loss of function mutation of
the REP1 has been known to mainly induce eye disease,
CHM, an X-linked recessive disease of the retina that results in
progressive degeneration of the retina, RPE, and choroid in
mammal.15,21,28,29 However, some reports showed that the
inactivation of REP1 gene led to multiple defects in the
cerebellum or hair cells of zebrafish,21,24 abnormal trophoblast
development and vascularization in mouse extra-embryonic
tissues,23 and aberrant intracellular transport in fibroblast and
monocyte of CHM patients.29 In this study, we verified that
REP1 has an important role in survival of intestinal cells in
Figure 5 siREP1-mediated cell death was alleviated with inhibition of FOXO3 in colon cancer cells. (a–e) HCT116 cells were transfected with siRNAs targeting REP1 and
FOXO3 as indicated. (a) Expressions of FOXO3, REP1, BIM, BAK, and p27 were analyzed by immunoblotting. β-ACTIN was included as an internal loading control. Numbers
below blots indicate the expression as measured by fold change. (b and c) Transfected cells were cultured in serum-starvation condition (0.1% FBS). (b) Number of live cells was
counted by trypan blue staining. (c) The frequency of apoptotic cells (active caspase-3+) was determined by flow cytometry analysis. (d–e) Transfected cells were treated with
20 uM of 5-FU for 24 h. (d) Number of live cells was counted by trypan blue staining. (e) The frequency of apoptotic (active caspase-3+) cells was determined by flow cytometry
analysis. All graphs represent two independent experiments performed in triplicate. Error bars represent S.D. from the mean. *Po0.01, **Po0.001
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addition to eyes or a variety of tissues in zebrafish. These
results essentially consist with previous report that rep1−/−
zebrafish shows the degenerative phenotypes in retina,
followed by multisystem disease, and eventually died at an
average of 4.8 dpf when the maternally derived REP1 in the
yolk sac is exhausted.18 Seabra and colleagues additionally
showed that the early embryonic lethality was explained by a
single rep1 gene in zebrafish.18
Intriguingly, the expression level of REP1 is upregulated in
human colon cancer tissues and cell lines compared with the
normal counterparts. These data present the possibility that
REP1 may function in tumorigenesis, especially cancer cell
survival in colon cancer. Overexpression of REP1 in HEK293
cells enhanced cell proliferation and reduced apoptosis in
serum-starved condition or during anti-cancer drug 5-FU
treatment, which implies that upregulation of REP1 is closely
associated with tumorigenesis aswell as chemo-resistance. In
the knockdown experiment, we found that REP1 is essential
for survival of colon cancer cells in serum-starved condition as
well as 5-FU-treated condition. It is interesting to note that
there was a little difference in survival of colon cancer cells
between control and REP1 silencing under normal serum
condition. In general, REP1 has a pivotal role in geranyl-
geranyl modification of most of Rab GTPases, which function
in vesicle trafficking.14,30 A number of Rab protein has been
shown to be involved in various stages of autophagy, which is a
highly conserved intracellular and lysosome-dependent
degradation process, and induced by various forms of cellular
stress including nutrient deprivation, reactive oxygen species
(ROS) or even DNA damage.31 REP1 also functions in
geranyl-geranyl modification of autophagy related Rab
proteins such as Rab1, Rab5, Rab7, and Rab11.32,33 It needs
to be further studied what Rab proteins cooperate with REP1
in normal and cancer cells. Meanwhile, both in yeast
Figure 6 REP1 negatively regulates the transcriptional activity of FOXO3 and the expression of FOXO3 target genes. (a and b) HCT116 cells were transfected with siRNAs
targeting GFP or REP1. (a) FOXO3 transcriptional activity was determined using the FHRE-Luc reporter system. The cells were transfected with the FHRE-Luc reporter. A vector
expressing β-galactosidase was co-transfected to ensure transfection efficiency and to normalize luciferase activity values. For analysis of the FOXO3 reporter activity in the cells,
it was normalized to the control cells transfected with the empty vector. (b) mRNA expression of BAK, BIM, and p27 was analyzed by real-time quantitative RT-PCR. (c) FOXO3
transcriptional activity was determined using the FHRE-Luc reporter system. HEK293 cells were transfected with the FHRE-Luc reporter, together with the indicated plasmids.
(d) HEK293 cells were transfected with empty vector (no), REP1 wild-type (WT), or REP1 mutant (Mut). mRNA expression of BAK, BIM, and p27 was analyzed by real-time
quantitative RT-PCR. Fold change was calculated relative to the expression level of mRNA in control cells. All graphs represent two independent experiments performed in
triplicate. Error bars represent standard deviations from the mean. *Po0.01, **Po0.001
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and vertebrates, the cell growth and division are governed by
environmental nutrient availability, and the conserved target of
rapamycin (TOR) signaling mediates the nutrient status to
critical cellular processes including ribosome biogenesis,
autophagy, and cell cycle entry into G0.34,35 Interestingly, in
yeast, MRS6, a yeast homolog of vertebrate choroideremia
(chm, REP1) gene, functions in integrating the secretion
system with TOR signaling and ribosome biogenesis in
response to extracellular nutrient level, and suggested as a
positive regulator of TORC1 through nuclear translocation of
Sfp1 which is downstream effector of TOR signaling.36,37
Hence, it is possible that REP1 may regulate cancer cell
survival in serum-starved condition by vesicle trafficking
independent manners as well as traditional vesicle trafficking
dependent manner.
In the course of elucidating how REP1 functions in survival
of colon cancer cells, we identified FOXO3 as a physical
interactor for REP1 by Y2H (Figure 3). FOXO3 is a member of
Forkhead box O (FoxO) transcription factors which are
involved in the regulation of metabolism, lifespan, cell cycle,
and apoptosis; moreover, in model organisms, their activity
also affects age-related diseases, such as diabetes and
cancer.38 Especially in cancer, FOXOs inhibit cell proliferation
and induce the expression of pro-apoptotic genes or death
ligands,39–41 and primarily function in response to environ-
mental changes, including growth factor deprivation, meta-
bolic stress (starvation) and oxidative stress.42–44 In this study,
we demonstrated that REP1 functions in colon cell survival
depending on the activity of FOXO3 under serum-starved or
5-FU induced oxidative stress conditions (Figure 5), by which
REP1 negatively regulates the transcriptional activity of
FOXO3 and the expression of FOXO3 target genes, including
BAK, BIM, and p27 (Figure 6).
Since it is well known that the transcriptional activity of
FOXOs is regulated through post-translational modifications,
including phosphorylation, acetylation, methylation and
Figure 7 REP1 inhibits nuclear trans-localization of FOXO3. HEK293 cells were transfected with RFP-FOXO3 together with empty vector (no), GFP-REP1WT, or GFP-REP1
Mut. Confocal fluorescent microscopy was used to evaluate the subcellular distribution of FOXO3 and REP1. Representative pictures are shown in (a), and the experimental
quantitation of subcellular localization of FOXO3 is shown in (b). Graph represents three independent experiments and error bars represent S.D. from the mean. **Po0.001
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ubiquitination, and/or coordinated shuttling of both FOXOs
and their regulators,38 we also examined the nuclear-
cytoplasmic localization of REP1 and FOXO3. Our observa-
tions that REP1 directly binds to FOXO3 proteins, and
REP1-dependent cytoplasmic re-localization of FOXO3 is
closely correlated with survival of colon cancer cells, are quite
similar to the previously proposed mechanisms which show
that nuclear-cytoplasmic shuttling of FOXOs is regulated by
Akt and 14-3-3.45,46 Taken together, these data indicate that
REP1 is a novel regulator for nuclear-cytoplasmic shuttling of
FOXO3, during which it regulates cell survival under stress or
starvation condition.
On the basis these new findings that REP1 confers
resistance to 5-FUwhich is first-line drug of colorectal cancers.
We believe that inhibition of REP1may be an effective strategy
for 5-FU-based cancer therapy. In this study, we provided
proof of this concept by knocking down REP1 in a xenograft
mouse model of human colon cancer. Notably, in this setting,
REP1 inhibition alone strongly retarded tumor growth, and
when it was combined with 5-FU treatment, it synergized the
anti-tumor effects. Our results indicate that REP1 inhibition is
employed as a sensitizer to enhance therapeutic effects of 5-
FU and suggest that REP1 could be a new therapeutic target
in combination treatment for colon cancer patients.
In summary, we demonstrated that REP1 is required for the
survival of intestinal cells in addition to eyes or a variety of cells
in zebrafish, and presented that REP1 also has important
roles in tumorigenesis, especially colon cancer cell survival
under stress conditions including nutrient starvation or 5-FU-
mediated stress conditions. We identified FOXO3 as a REP1
interacting protein by Y2H, and found that REP1 inhibits
nuclear trans-localization of FOXO3 through physically inter-
acting with FOXO3, thereby inhibiting FOXO3-mediated
apoptosis. Furthermore, we showed that REP1 silencing
combined with 5-FU treatment could lead to a synergic
retardation of tumor growth in a xenograft tumor model of
human cancer cells. Therefore, our data provide a new clinical
insight for treating colon cancers by regulating FOXO3 with
REP1, a novel oncogenic protein.
Materials and Methods
Zebrafish wild-type, mutant and transgenic lines, maintenance,
and immunostaining. Wild-type zebrafish used in this study had the Oregon
AB genetic background. The evanescence (eva rk10) mutant which is the mutant for
rab escort protein 1 (rep1)24 and Tg(flk:gfp)s843 (ref. 47) was maintained in
accordance with the accepted standard procedures48 approved by the IACUC at
National Cancer Center in Korea (permit number: NCC-15-116C). For whole mount
staining, zebrafish embryos were incubated with 0.006% of phenylthiourea (P7629,
Sigma, St. Louis, MO, USA) at 12 hpf (hours post fertilization) to prevent
pigmentation until 5 dpf (days post fertilization). After fixation in 4%
paraformaldehyde overnight at 4 °C, embryos were washed three times with
PBS, followed by 100% methanol immersion at − 20 °C. For TUNEL assays,
embryos were rehydrated progressively (75%, 50%, 25%, and 0% of methanol in
PBS), treated with proteinase K (10 mg/ml, for 30 min at room temperature). The
apoptotic cells in embryos were detected with the DeadEnd Colorimetric TUNEL
System (G7360, Promega, Madison, WI, USA) according to the manufacturer’s
instructions. For immunostaining, anti-phospho p44/42 MAPK (dp-ERK, 1/200
dilution, Rabbit monoclonal, #4370, Cell Signaling, Danvers, MA, USA) and
Figure 8 Inhibition of REP1 enhances the anti-tumor effect of 5-FU. (a) Schematic representation of the therapy regimen in mice implanted with HCT116 colon cancer cells.
Nude mice were inoculated subcutaneously with 1 × 106 HCT116 cells per mouse. Ten days following tumor challenge, siRNA CNP targeting GFP or REP1 (7 ug/mouse) was
injected intravenously, twice for 2 consecutive days. Chitosan hydrogels loaded with 5-FU (0.1 mg/kg) were administered intratumorally at day 14. (b) Tumor growth in mice
inoculated with HCT116 treated with the indicated reagents (five mice/group). (c) Tumor mass in mice at 23 days after challenge. Error bars represent S.D. from the mean.
*Po0.01, **Po0.001
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anti-cleaved caspase-3 (Asp175, 1/200, Rabbit monoclonal, #9661, Cell Signaling)
antibodies were used. The procedure for immunostaining was essentially the same
as that in a previous report.24 The secondary antibody used for visualization with
fluorescence was Alexa Fluor 488 or 555 goat-anti-rabbit antibody (1/400 dilution,
Molecular Probes, Invitrogen, Carlsbad, CA, USA). After three washes with PBST,
the samples were embedded in 1% low-melting-point agarose dissolved in PBS in a
glass-bottomed dish, and subjected to confocal imaging (Carl Zeiss LSM510 with
CCD camera; Carl Zeiss, Oberkochen, German).
Immunohistochemistry. Tissue microarrays (TMAs) were constructed from
formalin-fixed paraffin-embedded tissue blocks of 80 surgically resected colon
cancers with a manual tissue microarrayer (UniTMA Co Ltd, Seoul, Korea). TMAs
contained four 2.0 mm cores from three primary colon cancers and matched
nonadjacent normal colonic mucosa. The TMA sections were baked at 60 °C for
30 min and then deparaffinized with xylene and dehydrated through a graded
ethanol series. Antigen retrieval was achieved for 20 min in heat-activated antigen
retrieval pH 6.0 (Dako, Carpinteria, CA, USA) using a pressure cooker (Dako).
Endogenous peroxidase activity was quenched with 3% H2O2 in water for 15 min.
The sections were incubated with mouse monoclonal anti-REP1 antibodies
(sc-23905, Santa Cruz) at 1:500 for 1 h. Subsequently, antigen–antibody reaction
was detected with EnVision+ mouse Link System-HRP (Dako) and visualized with
DAB+ (3, 3′-Diaminobenzidine; Dako). Tissue sections were lightly counterstained
with hematoxylin and then examined by light microscopy. Negative controls
(substitution of primary antibody with TBS) were run simultaneously.
The evaluation of immunostaining was carried out using digital image analyzing
software version 4.5.1.324 (Visiopharm, Hoersholm, Denmark). Immunohistochemi-
cally stained slides were scanned using NanoZoomer 2.0 HT (Hamamatsu Photonics,
Hamamatsu, Japan) at × 20 objective magnification (0.5 μm resolution), and captured
digital images were then imported into the Visiopharm software. The intensity of
staining was categorized as 0, 1+, 2+, and 3+ according to the distribution pattern
across the TMA cores. The final histoscore was calculated by multiplying the intensity
and percentage of staining resulting in score of 0–300 as described previously.49
Statistic analyses were performed with SPSS version 21.0 for Windows (Chicago, IL,
USA). A P-valueo0.05 was considered statistically significant.
Mice. Six- to eight-week-old female nude mice were purchased from Central Lab.
Animal Inc. (Seoul, Korea). All mice were maintained and handled under the
protocol approved by the Korea University Institutional Animal Care and Use
Committee (KUIACUC-2014-175). All animal procedures were performed in
accordance with recommendations for the proper use and care of laboratory
animals.
Cells. The human colon cancer cells (LoVo, SNUC4, HT29, and HCT116) and
human embryonic kidney 293 (HEK 293) cells were purchased from American Type
Culture Collection (ATCC, Rockville, MD, USA). HCT116 and HEK293 cells were
cultured in DMEM (Thermo Scientific, Waltham, MA, USA) containing 100 units/ml
of penicillin-streptomycin and 10% fetal bovine serum (FBS). LoVo, SNUC4, and
HT29 cells were cultured in RPMI 1640 containing 100 units/ml of penicillin-
streptomycin and 10% FBS. All cells were grown at 37 °C in a 5% CO2 incubator/
humidified chamber. Normal fetal human colon cell line, FHC, was kindly provided
by Dr. JW Hyun (Jeju National University). Human colon FHC cells were cultured in
a 1 : 1 mixture of Ham’s F12 and DMEM containing HEPES (25 mM), cholera toxin
(10 ng/ml; Calbiochem-Novabiochem Corp., La Jolla, CA, USA), insulin (5 μg/ml),
transferrin (5 μg/ml), hydrocortisone (100 ng/ml), and 10% FCS.
DNA constructs. To make the full-length (hREP1-full, 1–653 a.a.) and mutant
(hREP1-S473X, 1–472 a.a., which corresponds to the zebrafish mutant protein of
evark10) human rep1 expression constructs, we performed PCR from HEK293T
cDNA using KOD-Plus-Neo polymerase (TOYOBO Co. Ltd., Osaka, Japan) with the
following primers: 5′-CCATCGATTATGGCGGATACTCTCCCTTCG-3′ (5′-primer for
hREP1-full and hREP1-S473X) and 5′-GTAGGCGCGCCTTCAGAGGACT
CCTCTAGGTT-3′ (3′-primer for hREP1-full), and 5′-TAGGCGCGCCAATCTGTTG
ACTGAATCTGTTTTTAG-3′ (3′-primer for hREP1-S473X). Each fragment was then
inserted into the Cla1 and Asc1 sites of pCS4+ vectors (3xFlag and EGFP).50 To
make the full-length human FOXO3a for expression in cells, we also performed
PCR with the following primers: 5′-AGATCGATATGGCAGAGGCACCGGC-3′
(5′-primer) and 5′-TAGGCGCGCCTGGCACCCAGCTCTGAGA-3′ (3′-primer), and
fused it to pCS4+ vectors (3xHA, and mRFP).
siRNA constructs. Synthetic small interfering RNA (siRNA) specific for GFP,
REP1, and FOXO3 were purchased from Bioneer (Daejeon, Korea); Non-specific
GFP (green fluorescent protein), 5′-GCAUCAAGGUGAACUUCAA-3′ (sense),
5′-UUGAAGUUCACCUUGAUGC-3′ (antisense), REP1, 5′-CCGGAGAGUUCUG
CAUGUU-3′ (sense), 5′-AACAUGCAGAACUCUCCGG-3′ (antisense), FOXO3, 5′-
GACGAUGAUGCGCCUCUCU-3′ (sense), 5′-AGAGAGGCGCAUCAUCGUC-3′
(antisense). For in vitro delivery, cells were transfected with 100 pmol of
synthesized siRNAs using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. For systemic in vivo delivery of siRNA into tumor cells,
we prepared the characterized CNP as described previously.51 Briefly, tripolypho-
sphate (0.25% w/v) and siRNA (1 ug/ul) were added into the RGD-Chitosan
solution, and the siRNA/RGD-CNPs were incubated at 4 °C for 40 min and collected
by centrifugation at 13 000 r.p.m. for 40 min at 4 °C. The pellet washed was three
times using sterile water. Isolated siRNA/RGD-CH-NP was intravenously injected
into HCT116-bearing nude mice.
Western blot analysis. Lysate extracted from a total of 1 × 105 cells was used
to perform western blot as described previously.43 Primary antibodies against REP1
(LS-B8700, LSBio, Seattle, WA, USA), Bim (#2819, Cell Signaling), BAK (#556396,
BD Biosciences, San Diego, CA, USA), BID (#2002, Cell Signaling), BAX (sc-493,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), BAD (#9292, Cell Signaling), p27
(sc-528, Santa Cruz), FLAG (M185-3L, MBL, Nagoya, Japan), FOXO3 (sc-11351,
Santa Cruz), HA (M180-3, MBL) and β-ACTIN (M177-3) were used in western
blotting, followed by the appropriate secondary antibodies conjugated with horseradish
peroxidase. Immunoreactive bands were developed using the chemiluminescence
ECL detection system (Elpis Biotech, Daejeon, Korea), and signals were detected
using a luminescent image analyzer (LAS-4000 Mini, Fujifilm, Tokyo, Japan). β-ACTIN
was included as an internal loading control. The intensity of the western blot signals
was quantified using Multi-gauge software (Fujifilm).
Flow cytometry analysis. 1 × 105 cells were harvested by trypsinization,
washed and re-suspended in PBS. To detect apoptotic cells, cells were then labeled
with PE-conjugated anti-active caspase-3 antibody (51-68655X, BD Biosciences),
according to the manufacturer’s instructions. The percentage of apoptotic cells was
analyzed using a FACSVerse flow cytometer (BD Biosciences) by determining the
active caspase-3+ cells. Data acquisition was performed on a FACSVerse flow
cytometer with BD FACSuite software.
Cell viability assay. Cell viability was determined by Trypan blue exclusion
assay and MTTassay. For Trypan blue exclusion assay, cells were harvested at the
indicated times and stained with 0.4% Trypan blue to exclude dead cells. The
number of live cells was counted using a hemocytometer and light microscopy.
Yeast two-hybrid (Y2H) assay and quantitation of protein–protein
interaction. For bait construction with human REP1, cDNA encoding full-length
human REP1 was cloned into the BamHI and NcoI restriction enzyme sites of the
pGilda/LexA yeast shuttle cloning vector. The bait pGilda/LexA-REP1 plasmid was
introduced into a yeast strain EGY48 [MATa, his3, trp1, ura3-52, leu2::pLeu2-
LexAop6/pSH18-34 (LexAop-lacZ reporter)] using a modified lithium acetate
protocol.52,53 Approximately 5.5 × 106 independent transformants were pooled. After
re-spreading on selection media (Ura-, His-, Trp-, Leu-) and X-gal-containing plates,
and obtaining six positive colonies, the purified plasmids were sequenced. A
homology search in the GenBank using the BLAST program identified that the
plasmids encoded FOXO3 (accession number: NM_001455.3). The human FOXO3
cDNA encoding a full-length gene was cloned into multi-cloning sites (MCS) of the
pJG4-5 plasmid vector, which included B42 fusion proteins (Clontech, Palo Alto, CA,
USA). The FOXO3 cDNAs encoding pJG4-5 fusion proteins were transformed into
yeast competent cells that already contained pGilda/LexA-REP1, while the
transformants were selected based on their tryptophan prototrophy (plasmid vector
marker) on a synthetic medium (Ura, His, Trp) containing 2% (w/v) glucose. Positive
protein–protein interactions were monitored as the formation of blue colonies on the
X-gal-containing medium as described previously.53 The binding activity of the
interaction was compared by calculating the relative expression level of ONPG
β-galactosidase.52
Immunoprecipitation. For co-immunoprecipitation of REP1 and FOXO3,
HEK293 cells expressing the indicated constructs were cultured for 48 h, and
whole-cell lysates were prepared with NP40 lysis buffer (50 mM Tris-HCL, pH 8.0,
5 mM EDTA, 150 mM NaCl, 1% NP-40, 1 mM PMSF) containing protease inhibitor.
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Immunoprecipitation was carried out by incubation with 1 μg of anti-HA (M180-3,
MBL), anti-FLAG (M185-3L, MBL) antibody or mouse IgG for 16 h. For
immunoprecipitation of endogenous REP1 or FOXO3, HCT116 cells were lysed
in NP40 lysis buffer containing protease inhibitor. Immunoprecipitation was carried
out by incubation with 1 μg of anti-REP1 (LS-B8700, LSBio), anti-FOXO3
(sc-11351, Santa Cruz) antibody or rabbit IgG for 16 h. The bound proteins were
eluted by boiling in SDS sample buffer and were detected by western blotting.
Real-time quantitative RT-PCR. Total RNA was isolated using RNeasy
Micro kit (Qiagen, Valencia, CA, USA), and the cDNAs were synthesized by reverse
transcriptase (RT) using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA),
according to the manufacturer’s recommended protocol. Real-time quantitative PCR
was performed using iQ SYBR Green super mix (Bio-Rad) with the following
specific primers; BIM, 5′-AGGCAATCACGGAGGTGAAG-3′ (forward) and 5′-TC
TGGTAGCAAAAGGGCCAG-3′ (reverse); BAK, 5′-TCATCGGGGACGACAT
CAAC-3′ (forward) and 5′-CAAACAGGCTGGTGGCAATC-3′ (reverse); p27, 5′-CA
GCTTGCCCGAGTTCTACT-3′ (forward) and 5′-TGTCCTCAGAGTTAGCCGGA-3′
(reverse); β-Actin, 5′-CGACAGGATGCAGAAGGAGA-3′ (forward) and 5′-TAG
AAGCATTTGCGGTGGAC-3′ (reverse) on a CFX96 real-time PCR detection
system. All real-time quantitative PCR experiments were performed in triplicate and
quantification cycle (Cq) values were determined using Bio-Rad CFX96 Manager
3.0 software. Relative quantification of the mRNA levels was performed using the
comparative Ct method with β-Actin as the reference gene.
Luciferase assay. To determine the transcriptional activity of FOXO3,
luciferase assay was performed as described previously,51 using FHRE-Luc, which
was a gift from Michael Greenberg (Addgene plasmid # 1789).54 Briefly, using
Lipofectamine 2000 (Invitrogen), cells were transfected with 100 ng of FHRE-Luc
reporter, and 100 ng of indicated constructs, together with 20 ng of CMV/β-
galactosidase plasmid to normalize transfection efficiency. After 24 h, cells were
washed with PBS and permeabilized with Cell Culture Lysis Reagent (Promega).
Luciferase activity was measured with a Turner Biosystems TD-20/20 luminometer
after addition of 40 μl of luciferase assay reagent (Promega). β-galactosidase
activity was measured with a uQuant microplate reader (BioTek, Winooski, VT, USA)
at 570 nm wavelength after addition of β-galactosidase assay reagent containing
1 mM chlorophenol red β-D-galactopyranoside substrate (Roche).
Immunofluorescence. To examine cellular localization of FOXO3, cells were
cultured on 2-well cell culture slides (#30102, SPL Life Science, Suwon, Korea) and
transfected with the indicated plasmid DNAs or siRNAs using Lipofectamine2000
(Invitrogen) according to the manufacturer's protocol. The transfected cells were
fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences) for 20 min at 4 °C.
After washing in 1 × Perm-wash buffer and nuclear counterstaining with DAPI,
localization of FOXO3 or REP1 was demonstrated under a confocal laser scanning
microscope (ZEISS LSM700, Carl Zeiss).
Tumor treatment experiments. Nude mice were inoculated subcutaneously
with 1 × 106 HCT116 cells per animal and siGFP- or siREP1-loaded CNPs (7 μg/
mouse) were administered via the tail vein at days 10 and 12. Fourteen days after
tumor challenge, chitosan hydrogels loaded with 5-FU (0.1 mg/kg) were administered
intratumorally. Mice were monitored for tumor burden for 23 days after challenge.
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